200,000+ products from a single source!
sales@angenechem.com
162359-55-9 | 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-
CAS No: 162359-55-9 Catalog No: AG001T0Z MDL No:MFCD14705150
Product Description
Catalog Number:
AG001T0Z
Chemical Name:
1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-
CAS Number:
162359-55-9
Molecular Formula:
C19H33NO2
Molecular Weight:
307.4708
MDL Number:
MFCD14705150
IUPAC Name:
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
InChI:
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
InChI Key:
KKGQTZUTZRNORY-UHFFFAOYSA-N
SMILES:
CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N
UNII:
3QN8BYN5QF
Properties
Complexity:
258
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
307.251g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
307.478g/mol
Monoisotopic Mass:
307.251g/mol
Rotatable Bond Count:
12
Topological Polar Surface Area:
66.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.2
Literature
| Title | Journal |
|---|---|
| Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. | Toxicology letters 20180701 |
| Disease modifying therapies for relapsing multiple sclerosis. | BMJ (Clinical research ed.) 20160822 |
| Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses. | Journal of medicinal chemistry 20160211 |
| FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. | Toxicology letters 20150702 |
| Simultaneous and dose dependent melanoma cytotoxic and immune stimulatory activity of betulin. | PloS one 20150101 |
| Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3. | Journal of neuroinflammation 20150101 |
| Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. | ACS medicinal chemistry letters 20141211 |
| Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation. | Toxicology and applied pharmacology 20141115 |
| FTY720 attenuates paraquat-induced lung injury in mice. | International immunopharmacology 20140801 |
| Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. | Nature neuroscience 20140701 |
| Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. | Journal of medicinal chemistry 20140626 |
| ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. | PloS one 20140101 |
| Modulators of the Sphingosine 1-phosphate receptor 1. | Bioorganic & medicinal chemistry letters 20131201 |
| Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod. | Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20130601 |
| Drugs in development for relapsing multiple sclerosis. | Drugs 20130501 |
| Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. | Journal of immunology (Baltimore, Md. : 1950) 20130401 |
| Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels. | British journal of pharmacology 20130301 |
| Early tolerability and safety of fingolimod in clinical practice. | Journal of the neurological sciences 20121215 |
| Fingolimod inhibits PDGF-B-induced migration of vascular smooth muscle cell by down-regulating the S1PR1/S1PR3 pathway. | Biochimie 20121201 |
| Effect of alkyl chain length on sphingosine kinase 2 selectivity. | Bioorganic & medicinal chemistry letters 20121115 |
| Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. | Multiple sclerosis (Houndmills, Basingstoke, England) 20121101 |
| Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. | Multiple sclerosis (Houndmills, Basingstoke, England) 20121101 |
| Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. | Multiple sclerosis (Houndmills, Basingstoke, England) 20121101 |
| Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. | Multiple sclerosis (Houndmills, Basingstoke, England) 20121101 |
| Focus on molecules: Sphingosine 1 Phosphate (S1P). | Experimental eye research 20121001 |
| Sudden unexpected death on fingolimod. | Multiple sclerosis (Houndmills, Basingstoke, England) 20121001 |
| Effects of FTY720 and rapamycin on inflammation in taurocholate-induced acute pancreatitis in the rat. | Pancreas 20121001 |
| New disease-modifying therapies and new challenges for MS. | Current neurology and neuroscience reports 20121001 |
| Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. | Birth defects research. Part A, Clinical and molecular teratology 20121001 |
| A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. | Chemistry & biology 20120921 |
| Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. | Neurology 20120911 |
| The safety risks of innovation: the FDA's Expedited Drug Development Pathway. | JAMA 20120905 |
| A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. | Multiple sclerosis (Houndmills, Basingstoke, England) 20120901 |
| A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? | Cardiovascular toxicology 20120901 |
| Fingolimod--a sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes. | Glia 20120901 |
| 4-aminopyridine toxicity: a case report and review of the literature. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20120901 |
| Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. | Acta neuropathologica 20120901 |
| Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice. | Vascular pharmacology 20120819 |
| S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. | Blood 20120816 |
| [Infections and fingolimod]. | Revista de neurologia 20120816 |
| Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. | The Journal of pharmacology and experimental therapeutics 20120801 |
| Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. | Transplant immunology 20120801 |
| A fluorescent assay for ceramide synthase activity. | Journal of lipid research 20120801 |
| Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. | International journal of clinical pharmacology and therapeutics 20120801 |
| Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis. | International journal of rheumatic diseases 20120801 |
| Population pharmacokinetics of fingolimod phosphate in healthy participants. | Journal of clinical pharmacology 20120701 |
| Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model. | Breast cancer research and treatment 20120701 |
| The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists. | Xenobiotica; the fate of foreign compounds in biological systems 20120701 |
| The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro. | International journal of molecular medicine 20120701 |
| [Basic mechanisms of action of fingolimod in relation to multiple sclerosis]. | Revista de neurologia 20120701 |
| Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. | Clinical therapeutics 20120701 |
| [Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 (fingolimod) in combination with betamethasone ointment in NC/Nga mice]. | Arerugi = [Allergy] 20120701 |
| Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. | Biochemical and biophysical research communications 20120622 |
| First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. | Drugs 20120618 |
| Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. | Bone marrow transplantation 20120601 |
| FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase. | British journal of pharmacology 20120601 |
| FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20120601 |
| Emerging disease-modifying therapies in multiple sclerosis. | Current treatment options in neurology 20120601 |
| Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. | Neurochemical research 20120601 |
| Overview of treatment options in multiple sclerosis. | The Journal of clinical psychiatry 20120601 |
| [Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials]. | Ideggyogyaszati szemle 20120530 |
| Structure of the first sphingosine 1-phosphate receptor. | Science signaling 20120522 |
| FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells. | Neuroscience letters 20120516 |
| Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways. | Journal of immunology (Baltimore, Md. : 1950) 20120515 |
| Building a better sphingosine kinase-1 inhibitor. | The Biochemical journal 20120515 |
| Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)). | Journal of medicinal chemistry 20120510 |
| [Multiple sclerosis: beyong first line therapies]. | Revue medicale suisse 20120502 |
| Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. | Current medical research and opinion 20120501 |
| MS clinical trials: what can subgroup analyses teach us? | The Lancet. Neurology 20120501 |
| Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. | The Lancet. Neurology 20120501 |
| Immunotherapies in neurologic disorders. | The Medical clinics of North America 20120501 |
| Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. | Oncogene 20120419 |
| [New disease-modifying and symptomatic therapies for multiple sclerosis]. | MMW Fortschritte der Medizin 20120419 |
| Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure. | American journal of physiology. Lung cellular and molecular physiology 20120415 |
| Drugs: An injection of hope. | Nature 20120412 |
| Autophagy induced by FTY720 promotes apoptosis in U266 cells. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411 |
| Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. | European journal of clinical pharmacology 20120401 |
| Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. | European journal of clinical pharmacology 20120401 |
| Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. | Journal of cellular biochemistry 20120401 |
| Reactive murine lymph nodes uniquely permit parenchymal access for T cells that enter via the afferent lymphatics. | The Journal of pathology 20120401 |
| Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. | The American journal of pathology 20120401 |
| Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. | Neuro-oncology 20120401 |
| FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. | The American journal of pathology 20120401 |
| Network analysis of randomized controlled trials in multiple sclerosis. | Clinical therapeutics 20120401 |
| [2012: Update on diagnosis and treatment of multiple sclerosis]. | Deutsche medizinische Wochenschrift (1946) 20120401 |
| Fingolimod: cardiovascular deaths. | Prescrire international 20120401 |
| Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis. | Future medicinal chemistry 20120401 |
| Structural requirements of membrane phospholipids for M-type potassium channel activation and binding. | The Journal of biological chemistry 20120323 |
| Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? | Neurology 20120320 |
| Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. | Cell and tissue research 20120301 |
| [(11)C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120301 |
| Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation. | Transplant immunology 20120301 |
| LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301 |
| FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? | Autophagy 20120301 |
| FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. | Multiple sclerosis (Houndmills, Basingstoke, England) 20120301 |
| Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. | Blood 20120301 |
| Fingolimod-associated macular edema: incidence, detection, and management. | Neurology 20120227 |
| Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug. | BMJ (Clinical research ed.) 20120223 |
| FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2). | The Journal of biological chemistry 20120217 |
| Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. | British journal of pharmacology 20120201 |
| Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue? | British journal of pharmacology 20120201 |
| Insights into the pharmacological relevance of lysophospholipid receptors. | British journal of pharmacology 20120201 |
| [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations]. | Der Nervenarzt 20120201 |
| Inhibitors of specific ceramide synthases. | Biochimie 20120201 |
| S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. | Molecular pharmacology 20120201 |
| Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. | The American journal of pathology 20120201 |
| Does fingolimod in multiple sclerosis patients cause macular edema? | Journal of neurology 20120201 |
| Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. | Cell cycle (Georgetown, Tex.) 20120201 |
| Fingolimod for multiple sclerosis. | Drug and therapeutics bulletin 20120201 |
| Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. | Archives of neurology 20120201 |
| Novel targeted therapies for mantle cell lymphoma. | Oncotarget 20120201 |
| Synthesis and immunomodulating activity of new analogues of fingolimod. | Archiv der Pharmazie 20120201 |
| New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. | Current opinion in neurology 20120201 |
| [Role of S1P acting both inside and outside the cells]. | Seikagaku. The Journal of Japanese Biochemical Society 20120201 |
| Fingolimod for multiple sclerosis. | The New England journal of medicine 20120126 |
| Fast simultaneous quantitative analysis of FTY720 and its metabolite FTY720-P in human blood by on-line solid phase extraction coupled with liquid chromatography-tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20120125 |
| [Neurology]. | Revue medicale suisse 20120111 |
| Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. | Clinical immunology (Orlando, Fla.) 20120101 |
| Sphingosine 1-phosphate in coagulation and inflammation. | Seminars in immunopathology 20120101 |
| The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. | Molecular biology reports 20120101 |
| Novel immunomodulators based on an oxazolin-2-one-4-carboxamide scaffold. | Bioorganic & medicinal chemistry letters 20120101 |
| Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. | Bioorganic & medicinal chemistry 20120101 |
| Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. | Multiple sclerosis (Houndmills, Basingstoke, England) 20120101 |
| Clinical pharmacokinetics of fingolimod. | Clinical pharmacokinetics 20120101 |
| Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. | Annual review of immunology 20120101 |
| Shining a light on intestinal traffic. | Clinical & developmental immunology 20120101 |
| Both exogenous commensal and endogenous self antigens stimulate T cell proliferation under lymphopenic conditions. | Cellular immunology 20120101 |
| Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. | Clinical & developmental immunology 20120101 |
| Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. | Current pharmaceutical design 20120101 |
| Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. | Clinical immunology (Orlando, Fla.) 20120101 |
| Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. | Trials 20120101 |
| FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. | PloS one 20120101 |
| [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists]. | Yao xue xue bao = Acta pharmaceutica Sinica 20120101 |
| Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient. | PloS one 20120101 |
| In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. | PloS one 20120101 |
| Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. | Molecular vision 20120101 |
| Novel therapies for aggressive B-cell lymphoma. | Advances in hematology 20120101 |
| Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. | Autoimmune diseases 20120101 |
| Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine. | PloS one 20120101 |
| Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. | PloS one 20120101 |
| Immune therapy of multiple sclerosis--future strategies. | Current pharmaceutical design 20120101 |
| Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis. | Current pharmaceutical design 20120101 |
| [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101 |
| Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro. | PloS one 20120101 |
| Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. | International journal of immunopathology and pharmacology 20120101 |
| Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice. | International journal of molecular sciences 20120101 |
| Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice. | Biological & pharmaceutical bulletin 20120101 |
| Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis. | Pharmaceutical statistics 20120101 |
| Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. | Drug design, development and therapy 20120101 |
| Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. | Wiener medizinische Wochenschrift (1946) 20120101 |
| Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. | Case reports in medicine 20120101 |
| Synthesis of a key intermediate for the preparation of FTY720 analogs. | Chemical & pharmaceutical bulletin 20120101 |
| FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. | Blood 20111222 |
| Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. | Circulation 20111213 |
| Current therapeutic options in pediatric multiple sclerosis. | Current treatment options in neurology 20111201 |
| Luminal CD4⁺ T cells penetrate gut epithelial monolayers and egress from lamina propria to blood circulation. | Gastroenterology 20111201 |
| Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. | Pharmacology & therapeutics 20111201 |
| Emerging oral drugs for relapsing-remitting multiple sclerosis. | Expert opinion on emerging drugs 20111201 |
| FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice. | American journal of reproductive immunology (New York, N.Y. : 1989) 20111101 |
| Delayed fingolimod-associated asystole. | Multiple sclerosis (Houndmills, Basingstoke, England) 20111101 |
| Targeting sphingosine-1-phosphate in hematologic malignancies. | Anti-cancer agents in medicinal chemistry 20111101 |
| Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. | Multiple sclerosis (Houndmills, Basingstoke, England) 20111101 |
| The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. | International immunopharmacology 20111101 |
| FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101 |
| Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. | Cancer research 20111101 |
| Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. | Current opinion in ophthalmology 20111101 |
| Oral treatment for multiple sclerosis. | The Lancet. Neurology 20111101 |
| Short-term immunossupressive treatment of the donor does not prevent ischemia-reperfusion kidney damage in the rat. | Transplantation proceedings 20111101 |
| [Multiple sclerosis: current therapies and future perspectives]. | Nihon rinsho. Japanese journal of clinical medicine 20111101 |
| Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose. | Journal of medicinal chemistry 20111013 |
| Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2. | Cellular and molecular neurobiology 20111001 |
| (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. | Cellular signalling 20111001 |
| Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. | American journal of physiology. Heart and circulatory physiology 20111001 |
| Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. | Current neurology and neuroscience reports 20111001 |
| Fingolimod treatment for multiple sclerosis patients What do we do with varicella? | Annals of neurology 20111001 |
| [The study of FTY720 on inducing apoptosis and autophagy in multiple myeloma cell line U266]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111001 |
| Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia. | Biochemical and biophysical research communications 20110923 |
| The effect of FTY720 in the Theiler's virus model of multiple sclerosis. | Journal of the neurological sciences 20110915 |
| Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. | Nature reviews. Urology 20110913 |
| Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. | Blood 20110908 |
| FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2. | The Journal of biological chemistry 20110902 |
| There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells. | Neurochemical research 20110901 |
| The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice. | Autoimmunity 20110901 |
| TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720. | International immunopharmacology 20110901 |
| Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. | The Journal of pharmacology and experimental therapeutics 20110901 |
| Emerging country pharmacology: a 10-year perspective from Naunyn-Schmiedeberg's Archives of Pharmacology. | Naunyn-Schmiedeberg's archives of pharmacology 20110901 |
| MS Forum/MS Over the Past 17 Years. | International MS journal 20110901 |
| Multiple Sclerosis: The Big Questions- The MS Forum Workshop. | International MS journal 20110901 |
| Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. | Molecular and cellular neurosciences 20110901 |
| FTY720 blocks egress of T cells in part by abrogation of their adhesion on the lymph node sinus. | Journal of immunology (Baltimore, Md. : 1950) 20110901 |
| Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis. | Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20110901 |
| A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). | Discovery medicine 20110901 |
| Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). | Expert review of clinical pharmacology 20110901 |
| Multiple sclerosis: pathogenesis and treatment. | Current neuropharmacology 20110901 |
| Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. | Current neuropharmacology 20110901 |
| NICE rules out NHS prescription of fingolimod for multiple sclerosis. | BMJ (Clinical research ed.) 20110810 |
| Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model. | Digestive diseases and sciences 20110801 |
| The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. | Pulmonary pharmacology & therapeutics 20110801 |
| Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. | Multiple sclerosis (Houndmills, Basingstoke, England) 20110801 |
| Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. | International journal of clinical practice 20110801 |
| Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B. | Current opinion in chemical biology 20110801 |
| Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. | CNS drugs 20110801 |
| Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. | Archives of dermatology 20110801 |
| Multiple sclerosis treatment: First oral drug, new antibody therapies. | JAAPA : official journal of the American Academy of Physician Assistants 20110801 |
| Redirected tumor-specific allogeneic T cells for universal treatment of cancer. | Blood 20110728 |
| Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. | Transplantation 20110715 |
| Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes. | The Journal of biological chemistry 20110715 |
| Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS. | Nature reviews. Neurology 20110712 |
| FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. | The European respiratory journal 20110701 |
| FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. | Autophagy 20110701 |
| A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate. | American journal of physiology. Renal physiology 20110701 |
| Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. | Journal of immunology (Baltimore, Md. : 1950) 20110701 |
| Discovery of S1P agonists with a dihydronaphthalene scaffold. | Bioorganic & medicinal chemistry letters 20110701 |
| The emerging role of Brazil in clinical trial conduct for transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110701 |
| Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis. | Scandinavian journal of immunology 20110601 |
| Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20110601 |
| New drugs 2011 part 2. | Nursing 20110601 |
| Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. | The Journal of clinical investigation 20110601 |
| Transforming multiple sclerosis trials into practical reality. | The Lancet. Neurology 20110601 |
| Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. | The Lancet. Neurology 20110601 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. | Pediatric transplantation 20110601 |
| [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia]. | Zhongguo shi yan xue ye xue za zhi 20110601 |
| FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. | The Journal of biological chemistry 20110527 |
| [Development of new therapies for multiple sclerosis]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20110506 |
| Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. | Multiple sclerosis (Houndmills, Basingstoke, England) 20110501 |
| Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110501 |
| Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. | Kidney international 20110501 |
| Managing MS in a changing treatment landscape. | Journal of neurology 20110501 |
| Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. | Annals of neurology 20110501 |
| American academy of neurology annual meeting. | International MS journal 20110501 |
| Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. | The American journal of managed care 20110501 |
| Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. | Journal of natural products 20110425 |
| Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720. | The Journal of biological chemistry 20110422 |
| Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. | Neurology 20110405 |
| BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution. | ChemMedChem 20110404 |
| Sphingosine kinase and sphingosine 1-phosphate in asthma. | Bioscience reports 20110401 |
| Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. | Advances in therapy 20110401 |
| Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. | The American journal of pathology 20110401 |
| Clarity and strength of implications for practice in medical journal articles: an exploratory analysis. | BMJ quality & safety 20110401 |
| Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial. | Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401 |
| In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. | Fertility and sterility 20110315 |
| Primary varicella zoster infection associated with fingolimod treatment. | Neurology 20110315 |
| Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter. | Cancer research 20110315 |
| Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. | Autoimmunity 20110301 |
| Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth. | Tissue engineering. Part A 20110301 |
| Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. | International immunopharmacology 20110301 |
| Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator. | Biochemical pharmacology 20110301 |
| The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue. | Experimental dermatology 20110301 |
| Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety. | Bioorganic & medicinal chemistry letters 20110301 |
| Principles of a new treatment algorithm in multiple sclerosis. | Expert review of neurotherapeutics 20110301 |
| Depressogenic effects of medications: a review. | Dialogues in clinical neuroscience 20110301 |
| Embryonic pig pancreatic tissue for the treatment of diabetes: potential role of immune suppression with 'off-the-shelf' third-party regulatory T cells. | Transplantation 20110227 |
| Impact of sphingosine 1-phosphate modulation on immune outcomes. | Neurology 20110222 |
| Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. | Neurology 20110222 |
| Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy. | Neurology 20110222 |
| Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. | Neurology 20110222 |
| The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. | Neurology 20110222 |
| Modulation of sphingosine 1-phosphate signaling in neurologic disease. | Neurology 20110222 |
| Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. | Circulation research 20110204 |
| [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system]. | Der Nervenarzt 20110201 |
| Emerging disease-modifying oral therapies for multiple sclerosis. | Journal of neuroimmunology 20110201 |
| Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation. | Autoimmunity reviews 20110201 |
| Roles for lysophospholipid S1P receptors in multiple sclerosis. | Critical reviews in biochemistry and molecular biology 20110201 |
| Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Fingolimod for the treatment of relapsing multiple sclerosis. | Expert review of neurotherapeutics 20110201 |
| Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. | Transplant international : official journal of the European Society for Organ Transplantation 20110201 |
| Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis. | Nature reviews. Neurology 20110201 |
| Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. | Annals of neurology 20110201 |
| [Current treatment of multiple sclerosis]. | Lege artis medicinae : uj magyar orvosi hirmondo 20110201 |
| The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. | The Journal of biological chemistry 20110121 |
| Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. | Biochemical and biophysical research communications 20110107 |
| CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110101 |
| Characterization of sphingosine-1-phosphate lyase activity by electrospray ionization-liquid chromatography/tandem mass spectrometry quantitation of (2E)-hexadecenal. | Analytical biochemistry 20110101 |
| Differential responses of human microglia and blood-derived myeloid cells to FTY720. | Journal of neuroimmunology 20110101 |
| Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs. | Molecular pharmacology 20110101 |
| Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. | CNS drugs 20110101 |
| Therapeutic approach to multiple sclerosis by novel oral drug. | Recent patents on inflammation & allergy drug discovery 20110101 |
| New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate. | Journal of the American Pharmacists Association : JAPhA 20110101 |
| Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls. | Current topics in medicinal chemistry 20110101 |
| Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). | Journal of medical Internet research 20110101 |
| Fingolimod provides long-term protection in rodent models of cerebral ischemia. | Annals of neurology 20110101 |
| [Immunosuppressive agents in kidney transplantation]. | Nihon Jinzo Gakkai shi 20110101 |
| Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. | Experimental & translational stroke medicine 20110101 |
| Current disease-modifying treatment of multiple sclerosis. | The Mount Sinai journal of medicine, New York 20110101 |
| Multiple sclerosis therapeutic pipeline: opportunities and challenges. | The Mount Sinai journal of medicine, New York 20110101 |
| Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. | Patient preference and adherence 20110101 |
| Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. | Core evidence 20110101 |
| Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. | Autoimmune diseases 20110101 |
| S1P is associated with protection in human and experimental cerebral malaria. | Molecular medicine (Cambridge, Mass.) 20110101 |
| Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. | PloS one 20110101 |
| Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice. | PloS one 20110101 |
| When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis. | Neuropsychiatric disease and treatment 20110101 |
| Development of oral immunomodulatory agents in the management of multiple sclerosis. | Drug design, development and therapy 20110101 |
| Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen. | Biological & pharmaceutical bulletin 20110101 |
| Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay. | PloS one 20110101 |
| Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. | Frontiers in pharmacology 20110101 |
| Selectivity and specificity of sphingosine 1-phosphate receptor ligands: 'off-targets' or complex pharmacology? | Frontiers in pharmacology 20110101 |
| FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. | PloS one 20110101 |
| Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| Placebo - More hatred than love. | Journal of neurosciences in rural practice 20110101 |
| FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. | Acta neurochirurgica. Supplement 20110101 |
| Fingolimod modulates microglial activation to augment markers of remyelination. | Journal of neuroinflammation 20110101 |
| Fingolimod. | Prescrire international 20110101 |
| Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. | Journal of medical economics 20110101 |
| The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis. | Autoimmune diseases 20110101 |
| A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. | PloS one 20110101 |
| Novel therapeutic approaches to autoimmune demyelinating disorders. | Current pharmaceutical design 20110101 |
| Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. | ASN neuro 20110101 |
| Author's Reply. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101 |
| Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. | Neuropsychiatric disease and treatment 20110101 |
| Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. | PloS one 20110101 |
| Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis. | Journal of pharmacy & bioallied sciences 20110101 |
| Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. | BMC neurology 20110101 |
| When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? | Multiple sclerosis international 20110101 |
| Optimal deconvolution of transcriptional profiling data using quadratic programming with application to complex clinical blood samples. | PloS one 20110101 |
| Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis. | Journal of signal transduction 20110101 |
| Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. | PloS one 20110101 |
| The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage. | BMC musculoskeletal disorders 20110101 |
| Where are the new medicines? The case for terrestrial microorganisms. | Journal of advanced pharmaceutical technology & research 20110101 |
| Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats. | PloS one 20110101 |
| Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. | PloS one 20110101 |
| Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab. | Neurology research international 20110101 |
| Modeling natural anti-inflammatory compounds by molecular topology. | International journal of molecular sciences 20110101 |
| Oral fingolimod (gilenya) for multiple sclerosis. | The Medical letter on drugs and therapeutics 20101229 |
| Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. | American journal of respiratory cell and molecular biology 20101201 |
| Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. | Immunopharmacology and immunotoxicology 20101201 |
| Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. | Transplant international : official journal of the European Society for Organ Transplantation 20101201 |
| T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract. | Nature medicine 20101201 |
| Understanding the effects of FTY720 on leukocyte trafficking. | Archives of neurology 20101201 |
| Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. | Archives of neurology 20101201 |
| Effect of FTY720 treatment on postischemic pancreatic microhemodynamics. | Transplantation proceedings 20101201 |
| FDA approves the first oral drug for reducing multiple sclerosis relapses. | Harvard women's health watch 20101201 |
| Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. | The Journal of biological chemistry 20101112 |
| FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. | Autophagy 20101101 |
| FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. | Cancer research 20101101 |
| Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. | Nature reviews. Drug discovery 20101101 |
| Novartis eyes oral MS drug as potential blockbuster. | Nature biotechnology 20101101 |
| [Role of T lymphocytes in ischemic brain injury]. | Rinsho shinkeigaku = Clinical neurology 20101101 |
| Design and synthesis of selective and potent orally active S1P5 agonists. | ChemMedChem 20101004 |
| (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. | Cellular signalling 20101001 |
| FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. | Cellular signalling 20101001 |
| Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. | Clinical immunology (Orlando, Fla.) 20101001 |
| Elimination of a hydroxyl group in FTY720 dramatically improves the phosphorylation rate. | Molecular pharmacology 20101001 |
| FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice. | The American journal of pathology 20101001 |
| Current and future role of interferon beta in the therapy of multiple sclerosis. | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20101001 |
| Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. | Archives of pharmacal research 20101001 |
| Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. | Cellular signalling 20100901 |
| Emerging therapies in relapsing-remitting multiple sclerosis. | Reviews on recent clinical trials 20100901 |
| PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. | Journal of cellular biochemistry 20100901 |
| Emerging oral therapies in multiple sclerosis. | Current neurology and neuroscience reports 20100901 |
| A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. | European journal of immunology 20100901 |
| The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720. | Biomaterials 20100901 |
| Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. | Glia 20100901 |
| Treatment options for multiple sclerosis: current and emerging therapies. | Pharmacotherapy 20100901 |
| Emerging oral agents for multiple sclerosis. | The American journal of managed care 20100901 |
| Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. | Current neuropharmacology 20100901 |
| Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. | Neurology 20100803 |
| FTY720 and central memory: out of sight, out of mind. | Neurology 20100803 |
| Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. | The Journal of experimental medicine 20100802 |
| Effect of combined treatment with FK506, FTY720, and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1. | Pediatric transplantation 20100801 |
| Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. | Clinical immunology (Orlando, Fla.) 20100801 |
| Treating multiple sclerosis with fingolimod or intramuscular interferon. | Expert opinion on pharmacotherapy 20100801 |
| Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. | Endocrinology 20100801 |
| FTY720 mediates cytochrome c release from mitochondria during rat thymocyte apoptosis. | Transplant immunology 20100801 |
| Update on emerging therapies for multiple sclerosis. | Expert review of neurotherapeutics 20100801 |
| Avoiding infusion therapy prime benefit of new MS drug. | Managed care (Langhorne, Pa.) 20100801 |
| Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. | Expert opinion on pharmacotherapy 20100701 |
| Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. | Brain : a journal of neurology 20100701 |
| Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. | Cancer research 20100701 |
| Fingolimod is a potential novel therapy for multiple sclerosis. | Nature reviews. Neurology 20100701 |
| Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. | British journal of pharmacology 20100701 |
| S1P(1) receptor agonists: Assessment of selectivity and current clinical activity. | Current opinion in drug discovery & development 20100701 |
| [Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)]. | Drugs of today (Barcelona, Spain : 1998) 20100701 |
| FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100615 |
| Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. | Neurology 20100615 |
| [Emerging treatments for multiple sclerosis]. | Revue medicale suisse 20100602 |
| FTY720 promotes local microvascular network formation and regeneration of cranial bone defects. | Tissue engineering. Part A 20100601 |
| Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. | Diabetes 20100601 |
| Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. | Journal of the American Society of Nephrology : JASN 20100601 |
| The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation. | The American journal of pathology 20100601 |
| Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. | The American journal of pathology 20100601 |
| New drug therapies for multiple sclerosis. | Current opinion in neurology 20100601 |
| Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. | International immunology 20100601 |
| ACP Journal Club. Oral fingolimod was more effective than intramuscular interferon for relapsing-remitting multiple sclerosis. | Annals of internal medicine 20100518 |
| ACP Journal Club. Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis. | Annals of internal medicine 20100518 |
| Oral cladribine and fingolimod for relapsing multiple sclerosis. | The New England journal of medicine 20100506 |
| Oral cladribine and fingolimod for relapsing multiple sclerosis. | The New England journal of medicine 20100506 |
| Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. | Transplant international : official journal of the European Society for Organ Transplantation 20100501 |
| Evaluation of experimental autoimmune uveitis in mice treated with FTY720. | Investigative ophthalmology & visual science 20100501 |
| Fingolimod for relapsing multiple sclerosis: an update. | Expert opinion on pharmacotherapy 20100501 |
| Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. | Drugs of today (Barcelona, Spain : 1998) 20100501 |
| Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate. | Journal of medicinal chemistry 20100422 |
| FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. | Biochemical and biophysical research communications 20100409 |
| FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. | Cancer immunology, immunotherapy : CII 20100401 |
| Targeting the sphingolipid signaling pathway in stroke. | Stroke 20100401 |
| Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs. | Bioorganic & medicinal chemistry letters 20100401 |
| [How rare is tuberculosis?]. | Medizinische Monatsschrift fur Pharmazeuten 20100401 |
| [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. | Medizinische Monatsschrift fur Pharmazeuten 20100401 |
| Current and future disease-modifying therapies in multiple sclerosis. | International journal of clinical practice 20100401 |
| Multiple sclerosis: closing in on an oral treatment. | Nature 20100318 |
| FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. | Circulation research 20100305 |
| [Progress of therapy in patients with multiple sclerosis]. | MMW Fortschritte der Medizin 20100304 |
| United airways: circulating Th2 effector cells in an allergic rhinitis model are responsible for promoting lower airways inflammation. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20100301 |
| Discovery of a novel series of potent S1P1 agonists. | Bioorganic & medicinal chemistry letters 20100301 |
| S1P receptor mediated activity of FTY720 phosphate mimics. | Bioorganic & medicinal chemistry letters 20100301 |
| New drugs may improve, complicate treatment for multiple sclerosis. | Nature medicine 20100301 |
| Multiple sclerosis - established and novel therapeutic approaches. | Central nervous system agents in medicinal chemistry 20100301 |
| Cell phenotype evaluation at various sites after skin transplantation and FTY720 plus sirolimus therapy. | Transplantation proceedings 20100301 |
| Leishmania (Leishmania) amazonensis infection in mice treated with FTY720. | Transplantation proceedings 20100301 |
| Sirolimus in combination with FTY720: analysis of urinary and serum parameters. | Transplantation proceedings 20100301 |
| Cytoprotective Actions of FTY720 Modulate Severe Preservation Reperfusion Injury in Rat Renal Transplants. | Transplantation 20100227 |
| Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. | Virology 20100220 |
| Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. | American journal of respiratory and critical care medicine 20100215 |
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. | The New England journal of medicine 20100204 |
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. | The New England journal of medicine 20100204 |
| Oral therapy for multiple sclerosis--sea change or incremental step? | The New England journal of medicine 20100204 |
| FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. | Journal of neuroscience research 20100201 |
| FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. | Journal of molecular and cellular cardiology 20100201 |
| Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. | Stroke 20100201 |
| Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. | Multiple sclerosis (Houndmills, Basingstoke, England) 20100201 |
| Emerging multiple sclerosis oral therapies. | Neurology 20100105 |
| A functional role for CCR6 on proallergic T cells in the gastrointestinal tract. | Gastroenterology 20100101 |
| FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration. | Laboratory investigation; a journal of technical methods and pathology 20100101 |
| Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. | Clinical neuropharmacology 20100101 |
| [FTY720-induced lymphocyte apoptosis inhibits acute graft versus host disease in rat small bowel transplantation]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100101 |
| Role of platelets in neuroinflammation: a wide-angle perspective. | Journal of neuroinflammation 20100101 |
| Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. | Patient preference and adherence 20100101 |
| A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. | PloS one 20100101 |
| Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. | Arthritis research & therapy 20100101 |
| Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. | Therapeutics and clinical risk management 20100101 |
| Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20100101 |
| Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20100101 |
| Naïve T cells re-distribute to the lungs of selectin ligand deficient mice. | PloS one 20100101 |
| Arthritis: where are the T cells? | Arthritis research & therapy 20100101 |
| Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. | Drug design, development and therapy 20100101 |
| Multiple sclerosis therapies: molecular mechanisms and future. | Results and problems in cell differentiation 20100101 |
| Disease-modifying therapies in relapsing-remitting multiple sclerosis. | Neuropsychiatric disease and treatment 20100101 |
| Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. | Therapeutics and clinical risk management 20100101 |
| Innate pathways of immune activation in transplantation. | Journal of transplantation 20100101 |
| Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis. | International journal of molecular sciences 20100101 |
| Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. | Neuropsychiatric disease and treatment 20100101 |
| FTY720-induced suicidal erythrocyte death. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20100101 |
| New approaches in the management of multiple sclerosis. | Drug design, development and therapy 20100101 |
| Disease modifying agents for multiple sclerosis. | The open neurology journal 20100101 |
| Emerging therapies for treatment of multiple sclerosis. | Journal of inflammation research 20100101 |
| Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720. | Pathology oncology research : POR 20091201 |
| FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. | Journal of neurotrauma 20091201 |
| T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion? | Neurosurgery 20091201 |
| Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats. | The Tohoku journal of experimental medicine 20091201 |
| Systemically circulating colitogenic memory CD4+T cells may be an ideal target for the treatment of inflammatory bowel diseases. | The Keio journal of medicine 20091201 |
| The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. | Biochemical and biophysical research communications 20091113 |
| Activation of the lung S1P(1) receptor reduces allergen-induced plasma leakage in mice. | British journal of pharmacology 20091101 |
| FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. | British journal of pharmacology 20091101 |
| [Multiple sclerosis, the therapeutic arsenal of today and tomorrow]. | Soins; la revue de reference infirmiere 20091101 |
| News & views in ... Immunotherapy. | Immunotherapy 20091101 |
| Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog. | Transplantation 20091027 |
| T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. | The Journal of experimental medicine 20091026 |
| FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. | Neuropathology and applied neurobiology 20091001 |
| Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. | The Journal of pharmacology and experimental therapeutics 20091001 |
| Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. | Stroke 20091001 |
| Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. | American journal of physiology. Cell physiology 20091001 |
| The future of multiple sclerosis therapy. | Pharmacological research 20091001 |
| Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. | Journal of immunology (Baltimore, Md. : 1950) 20091001 |
| [Fingolimod - a new immunomodulator]. | Deutsche medizinische Wochenschrift (1946) 20091001 |
| New oral drugs for multiple sclerosis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001 |
| Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. | Journal of neuroimmunology 20090929 |
| The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. | Journal of immunology (Baltimore, Md. : 1950) 20090915 |
| Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. | American journal of physiology. Renal physiology 20090901 |
| Fragile maintenance of allograft tolerance induced by lymphocyte sequestration and co-stimulation blockade. | Transplant immunology 20090901 |
| [Role of sphingosine 1-phosphate receptor signaling in hematopoietic stem/progenitor cell transmigration]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090901 |
| Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs. | Bioorganic & medicinal chemistry 20090815 |
| Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. | The Journal of investigative dermatology 20090801 |
| Langerhans cell migration: not necessarily always at the center of the skin sensitization universe. | The Journal of investigative dermatology 20090801 |
| [Molecular target drug development for curing multiple sclerosis]. | Brain and nerve = Shinkei kenkyu no shinpo 20090801 |
| Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. | Cardiovascular research 20090715 |
| Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. | Journal of medicinal chemistry 20090709 |
| Pig embryonic pancreatic tissue as a source for transplantation in diabetes: transient treatment with anti-LFA1, anti-CD48, and FTY720 enables long-term graft maintenance in mice with only mild ongoing immunosuppression. | Diabetes 20090701 |
| The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. | American journal of physiology. Renal physiology 20090701 |
| Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090701 |
| Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. | Clinical and experimental immunology 20090701 |
| Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. | The Journal of biological chemistry 20090612 |
| Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. | Neuron 20090611 |
| FTY720 and lung tumor development. | International immunopharmacology 20090601 |
| Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. | Nature chemical biology 20090601 |
| [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20090601 |
| Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720. | Pathology international 20090601 |
| [FTY720 reduces peritubular micrangium loss in renal interstitial fibrotic rats]. | Zhonghua er ke za zhi = Chinese journal of pediatrics 20090601 |
| Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer. | Anti-cancer agents in medicinal chemistry 20090501 |
| Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720. | The Journal of organic chemistry 20090417 |
| Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists. | Bioorganic & medicinal chemistry letters 20090415 |
| FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. | Brain pathology (Zurich, Switzerland) 20090401 |
| Immunosuppressive therapy and post-transplant malignancy. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090401 |
| Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques. | The Journal of antimicrobial chemotherapy 20090401 |
| Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond. | European journal of immunology 20090401 |
| Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice. | Cell biology international 20090401 |
| [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20090401 |
| Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. | Nature 20090326 |
| B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis. | Immunity 20090320 |
| Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. | Neurology 20090317 |
| Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. | The Journal of pharmacology and experimental therapeutics 20090301 |
| Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats. | Experimental neurology 20090301 |
| FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells. | Transplantation proceedings 20090301 |
| FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. | The Journal of biological chemistry 20090227 |
| Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. | Journal of clinical pharmacology 20090201 |
| Trial watch: Phase III promise for oral multiple sclerosis therapy. | Nature reviews. Drug discovery 20090201 |
| [An additional role of FTY720 in chronic colitis]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20090201 |
| [Therapeutic advances in neurology]. | Revue medicale suisse 20090107 |
| Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. | Neurology 20090106 |
| The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an 'immature' vascular maturation factor to a 'mature' mediator of lymphocyte behavior and function. | Immunologic research 20090101 |
| Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. | Kidney international 20090101 |
| An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation. | Clinical and experimental immunology 20090101 |
| Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. | Journal of neuroinflammation 20090101 |
| [Lysophospholipid mediators]. | Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20090101 |
| T regulatory cells: an overview and intervention techniques to modulate allergy outcome. | Clinical and molecular allergy : CMA 20090101 |
| The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. | Annals of transplantation 20090101 |
| Review of teriflunomide and its potential in the treatment of multiple sclerosis. | Neuropsychiatric disease and treatment 20090101 |
| Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. | Arthritis research & therapy 20090101 |
| FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. | Clinical transplantation 20090101 |
| Recent developments in multiple sclerosis therapeutics. | BMC medicine 20090101 |
| Promising treatments of tomorrow for multiple sclerosis. | Annals of Indian Academy of Neurology 20090101 |
| New oral disease-modifying therapies for multiple sclerosis. | F1000 medicine reports 20090101 |
| Assessing cost-effectiveness in the management of multiple sclerosis. | ClinicoEconomics and outcomes research : CEOR 20090101 |
| Impaired initiation of contact hypersensitivity by FTY720. | The Journal of investigative dermatology 20081201 |
| FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow. | European journal of immunology 20081201 |
| Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine. | Transplantation proceedings 20081201 |
| Central nervous system-directed effects of FTY720 (fingolimod). | Journal of the neurological sciences 20081115 |
| Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies. | Clinical neurology and neurosurgery 20081101 |
| Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival. | Transplant immunology 20081101 |
| A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. | Brain : a journal of neurology 20081101 |
| A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate. | Biochemical and biophysical research communications 20081031 |
| FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. | Neurology 20081014 |
| Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. | The American journal of pathology 20081001 |
| The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. | The Journal of infectious diseases 20081001 |
| Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. | Archives of ophthalmology (Chicago, Ill. : 1960) 20081001 |
| FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. | Diabetes, obesity & metabolism 20080901 |
| Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. | Biochimica et biophysica acta 20080901 |
| Sphingosine 1-phosphate chemical biology. | Biochimica et biophysica acta 20080901 |
| Emerging oral drugs for multiple sclerosis. | Expert opinion on emerging drugs 20080901 |
| TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity. | Bioorganic & medicinal chemistry 20080815 |
| Immunology: Surprising side effects. | Nature 20080814 |
| Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection. | Nature 20080814 |
| The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. | British journal of clinical pharmacology 20080801 |
| Infections cast cloud over Novartis' MS therapy. | Nature biotechnology 20080801 |
| Azathioprine in multiple sclerosis. | Mini reviews in medicinal chemistry 20080801 |
| Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype. | The Journal of investigative dermatology 20080701 |
| Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues. | ChemMedChem 20080701 |
| Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P. | Genes to cells : devoted to molecular & cellular mechanisms 20080701 |
| FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression. | Biochemical and biophysical research communications 20080613 |
| Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury. | Neuropathology and applied neurobiology 20080601 |
| Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. | Journal of immunology (Baltimore, Md. : 1950) 20080601 |
| Antinociceptive activity of the S1P-receptor agonist FTY720. | Journal of cellular and molecular medicine 20080601 |
| Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. | Biological & pharmaceutical bulletin 20080601 |
| [Overview of MS: proposal of new MS definition/classification and review of the results of recent clinical trials]. | Nihon rinsho. Japanese journal of clinical medicine 20080601 |
| 'Inside-out' signaling of sphingosine-1-phosphate: therapeutic targets. | Pharmacological reviews 20080601 |
| Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. | Transplantation proceedings 20080601 |
| Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. | Transplantation proceedings 20080601 |
| New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. | Biochemical pharmacology 20080515 |
| The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. | European journal of clinical pharmacology 20080501 |
| Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. | International immunology 20080501 |
| FTY720 (fingolimod) for relapsing multiple sclerosis. | Expert review of neurotherapeutics 20080501 |
| The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen. | Journal of immunology (Baltimore, Md. : 1950) 20080415 |
| Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses. | Journal of immunology (Baltimore, Md. : 1950) 20080415 |
| FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. | Experimental neurology 20080401 |
| Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. | Pancreas 20080401 |
| Synthesis of the key intermediate, diethyl 2-acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the immunomodulatory agent FTY720 (fingolimod). | Chemical & pharmaceutical bulletin 20080401 |
| Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. | Transplantation proceedings 20080401 |
| Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. | Biochimica et biophysica acta 20080301 |
| A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod. | Journal of clinical pharmacology 20080301 |
| [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080301 |
| FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. | Cancer research 20080215 |
| Non-specific anti-proliferative effect of FTY720, a derivative of fungal metabolite from Iscaria sinclarii. | Archives of pharmacal research 20080201 |
| FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. | Blood 20080101 |
| FTY720 modulates human oligodendrocyte progenitor process extension and survival. | Annals of neurology 20080101 |
| Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. | Pharmacology & therapeutics 20080101 |
| Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. | British journal of pharmacology 20080101 |
| Follicular shuttling of marginal zone B cells facilitates antigen transport. | Nature immunology 20080101 |
| The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. | Nature immunology 20080101 |
| Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1. | Surgery today 20080101 |
| Antibody-mediated rejection with a striking interstitial monocyte/macrophage infiltration in a renal allograft under FTY720 treatment. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20080101 |
| Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. | Archives of ophthalmology (Chicago, Ill. : 1960) 20080101 |
| Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. | Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20080101 |
| FTY720 treatment in experimentally urethane-induced lung tumors. | Journal of experimental therapeutics & oncology 20080101 |
| Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. | Reviews on recent clinical trials 20080101 |
| Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. | The Mount Sinai journal of medicine, New York 20080101 |
| Cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models. | Immunopharmacology and immunotoxicology 20080101 |
| Disease-modifying agents for multiple sclerosis: recent advances and future prospects. | Drugs 20080101 |
| [Cordyceps sinensis, a fungi used in the Chinese traditional medicine]. | Revista iberoamericana de micologia 20071231 |
| Evaluation of stem cell administration in a model of kidney ischemia-reperfusion injury. | International immunopharmacology 20071215 |
| Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist. | Journal of medicinal chemistry 20071213 |
| [Regulation of immunity by sphingosine 1-phosphate and its G protein-coupled receptors--review]. | Zhongguo shi yan xue ye xue za zhi 20071201 |
| FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury. | Transplantation proceedings 20071201 |
| Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes. | Transplantation proceedings 20071201 |
| Therapeutic targeting of leukocyte trafficking across the blood-brain barrier. | Inflammation & allergy drug targets 20071201 |
| [Effect of FTY720 on glomerulosclerosis and expression of cell cycle regulatory proteins in subtotally nephrectomized rats]. | Zhonghua er ke za zhi = Chinese journal of pediatrics 20071201 |
| Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. | European journal of pharmacology 20071114 |
| Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). | Blood 20071101 |
| Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. | The Journal of pharmacology and experimental therapeutics 20071101 |
| The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. | The Journal of pharmacology and experimental therapeutics 20071101 |
| Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. | Arteriosclerosis, thrombosis, and vascular biology 20071101 |
| Sphingosine-1 phosphate signaling regulates positioning of dendritic cells within the spleen. | Journal of immunology (Baltimore, Md. : 1950) 20071101 |
| Synthesis and spectral properties of cholesterol- and FTY720-containing boron dipyrromethene dyes. | The Journal of organic chemistry 20071026 |
| FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. | Brain research bulletin 20071019 |
| FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. | Transplantation 20071015 |
| [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. | Der Nervenarzt 20071001 |
| Fingolimod: a novel immunosuppressant for multiple sclerosis. | The Annals of pharmacotherapy 20071001 |
| The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers. | Transplant international : official journal of the European Society for Organ Transplantation 20071001 |
| Emerging therapies for multiple sclerosis. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20071001 |
| Effect of FTY720 on apoptosis of smooth muscle cells. | Transplantation proceedings 20071001 |
| FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. | Cancer letters 20070908 |
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. | The Journal of clinical investigation 20070904 |
| Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070901 |
| Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. | Cellular signalling 20070801 |
| Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. | Journal of neurochemistry 20070801 |
| The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801 |
| Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20070801 |
| Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. | Journal of immunology (Baltimore, Md. : 1950) 20070801 |
| FTY720: a most promising immunosuppressant modulating immune cell functions. | Mini reviews in medicinal chemistry 20070801 |
| FTY720 improves survival after transient ischemia and reperfusion of the hind limbs. | The Journal of trauma 20070801 |
| The immunomodulator FTY720 is phosphorylated and released from platelets. | European journal of pharmacology 20070730 |
| Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. | Transplantation 20070727 |
| FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. | Molecular immunology 20070701 |
| Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors. | Naunyn-Schmiedeberg's archives of pharmacology 20070701 |
| Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. | Pharmacology & therapeutics 20070701 |
| FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. | FEBS letters 20070626 |
| S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. | American journal of physiology. Renal physiology 20070601 |
| The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma. | International immunology 20070601 |
| Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. | Expert opinion on pharmacotherapy 20070601 |
| Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. | The Journal of biological chemistry 20070525 |
| The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. | Journal of cellular biochemistry 20070501 |
| Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production. | Blood 20070501 |
| Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. | Journal of immunology (Baltimore, Md. : 1950) 20070501 |
| Novel oral agents for multiple sclerosis. | Current neurology and neuroscience reports 20070501 |
| Immunology. The sources of a lipid conundrum. | Science (New York, N.Y.) 20070413 |
| Mechanism of mitochondrial 7A6 antigen exposure triggered by distinct apoptotic pathways: involvement of caspases. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20070401 |
| FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism. | British journal of pharmacology 20070401 |
| Current perspectives on FTY720. | Expert opinion on investigational drugs 20070401 |
| Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. | Neuropharmacology 20070401 |
| Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. | The Journal of biological chemistry 20070323 |
| Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. | Journal of immunology (Baltimore, Md. : 1950) 20070315 |
| Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. | Transplantation 20070315 |
| Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. | The Journal of biological chemistry 20070309 |
| The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. | Arteriosclerosis, thrombosis, and vascular biology 20070301 |
| Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. | Biopharmaceutics & drug disposition 20070301 |
| Tipping the gatekeeper: S1P regulation of endothelial barrier function. | Trends in immunology 20070301 |
| FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. | Expert opinion on investigational drugs 20070301 |
| Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. | European journal of clinical investigation 20070301 |
| FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model. | Transplantation proceedings 20070301 |
| FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration. | Transplantation proceedings 20070301 |
| Chemokines and chemokine receptors in renal transplantation--from bench to bedside. | Acta physiologica Hungarica 20070301 |
| FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury. | Journal of cellular and molecular medicine 20070301 |
| FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. | Journal of immunology (Baltimore, Md. : 1950) 20070215 |
| The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. | Blood 20070201 |
| Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. | Arteriosclerosis, thrombosis, and vascular biology 20070201 |
| Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. | International journal of oncology 20070201 |
| Oral pharmacokinetic and pharmacodynamic effects of FTY720 in cats. | Journal of veterinary pharmacology and therapeutics 20070201 |
| Is fingolimod an advancement in the treatment of multiple sclerosis? KAPPOS L, ANTEL J, COMI G. et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355:1124-1140. | Expert opinion on pharmacotherapy 20070201 |
| Ethnic sensitivity study of fingolimod in white and Asian subjects. | International journal of clinical pharmacology and therapeutics 20070201 |
| [Effect of mono and combination therapy with FTY720 and ICAM-1 mAb for mouse-to-rat cardiac xenotransplantation]. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20070201 |
| FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. | Circulation 20070130 |
| Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. | Bioorganic & medicinal chemistry letters 20070115 |
| FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. | European journal of immunology 20070101 |
| Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. | International immunopharmacology 20070101 |
| Multiple sclerosis: new insights and therapeutic progress. | The Lancet. Neurology 20070101 |
| Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. | The American journal of pathology 20070101 |
| New immunosuppresor strategies in the treatment of murine lupus nephritis. | Lupus 20070101 |
| FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. | Anticancer research 20070101 |
| Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice. | Microsurgery 20070101 |
| Oral disease-modifying treatments for multiple sclerosis: the story so far. | CNS drugs 20070101 |
| Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. | Journal of biochemical and molecular toxicology 20070101 |
| Induction therapy in pediatric renal transplant recipients: an overview. | Paediatric drugs 20070101 |
| Sphingosine-1-phosphate signaling and the skin. | American journal of clinical dermatology 20070101 |
| FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. | Perspectives in medicinal chemistry 20070101 |
| Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. | Transplantation 20061227 |
| FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. | International immunopharmacology 20061220 |
| FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function. | International immunopharmacology 20061220 |
| Tacrolimus in combination with FTY720--an analysis of renal and blood parameters. | International immunopharmacology 20061220 |
| FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20061201 |
| Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation. | Transplantation proceedings 20061201 |
| Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function. | Transplantation proceedings 20061201 |
| Comparative quantification of sphingolipids and analogs in biological samples by high-performance liquid chromatography after chloroform extraction. | Analytical biochemistry 20061115 |
| Measurement and stability of FTY720 in human whole blood by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061107 |
| Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. | The Journal of clinical investigation 20061101 |
| Effect of FTY720 in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes in gut-associated lymphoid tissues. | Transplantation proceedings 20061101 |
| The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. | Expert review of neurotherapeutics 20061101 |
| Bioactive sphingolipids in the modulation of the inflammatory response. | Pharmacology & therapeutics 20061001 |
| Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation. | Clinical and experimental immunology 20061001 |
| The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. | Oncology reports 20061001 |
| Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. | The New England journal of medicine 20060914 |
| Oral fingolimod (FTY720) for relapsing multiple sclerosis. | The New England journal of medicine 20060914 |
| Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. | Drug metabolism and disposition: the biological fate of chemicals 20060901 |
| FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. | American journal of physiology. Gastrointestinal and liver physiology 20060801 |
| FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060801 |
| Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. | Nature chemical biology 20060801 |
| FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. | Journal of clinical pharmacology 20060801 |
| [Multifunctional sphingolipid, sphingosine (long-chain base) 1-phosphate: physiological role, metabolism, and intracellular dynamics]. | Seikagaku. The Journal of Japanese Biochemical Society 20060801 |
| Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. | Bioorganic & medicinal chemistry letters 20060715 |
| Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. | Molecular pharmacology 20060701 |
| Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. | Biochemical and biophysical research communications 20060623 |
| Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720. | Bioorganic & medicinal chemistry 20060615 |
| Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. | American journal of physiology. Renal physiology 20060601 |
| Pulmonary and vascular pharmacology of sphingosine 1-phosphate. | Current opinion in pharmacology 20060601 |
| Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. | European journal of immunology 20060601 |
| In vitro evaluation of the effect of a novel immunosuppressive agent, FTY720, on the function of feline neutrophils. | American journal of veterinary research 20060401 |
| Evidence that FTY720 induces rat thymocyte apoptosis. | Transplant immunology 20060401 |
| FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells. | Transplant immunology 20060401 |
| FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice. | Transplantation proceedings 20060401 |
| A photoreactive analogue of the immunosuppressant FTY720. | The Journal of organic chemistry 20060303 |
| Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060301 |
| FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. | Cancer letters 20060220 |
| Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. | Blood 20060215 |
| Enhanced FTY720-mediated lymphocyte homing requires G alpha i signaling and depends on beta 2 and beta 7 integrin. | Journal of immunology (Baltimore, Md. : 1950) 20060201 |
| Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. | Journal of clinical pharmacology 20060201 |
| [Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants]. | Nihon rinsho. Japanese journal of clinical medicine 20060201 |
| Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. | Cellular & molecular immunology 20060201 |
| Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. | Journal of immunology (Baltimore, Md. : 1950) 20060115 |
| NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies. | Bioorganic & medicinal chemistry letters 20060101 |
| The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. | British journal of pharmacology 20060101 |
| Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. | Journal of immunology (Baltimore, Md. : 1950) 20060101 |
| Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. | Cancer research 20060101 |
| The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. | Archivum immunologiae et therapiae experimentalis 20060101 |
| Immunotherapy for De Novo renal transplantation: what's in the pipeline? | Drugs 20060101 |
| FTY720 (fingolimod) in renal transplantation. | Clinical transplantation 20060101 |
| Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. | Clinical transplantation 20060101 |
| Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy. | Current pharmaceutical design 20060101 |
| FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. | International journal of cancer 20051220 |
| The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. | Journal of immunology (Baltimore, Md. : 1950) 20051215 |
| FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. | Pharmacology & therapeutics 20051201 |
| Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. | European journal of immunology 20051201 |
| Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. | Journal of immunology (Baltimore, Md. : 1950) 20051201 |
| FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051201 |
| Multiple sclerosis poses tough drug development challenges. | Drug discovery today 20051201 |
| Use of FTY 720 and ICAM-1 antisense oligonucleotides for attenuating chronic renal damage secondary to ischemia-reperfusion injury. | Transplantation proceedings 20051201 |
| Effect of FTY720 in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1. | Transplantation proceedings 20051201 |
| FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. | Cellular & molecular immunology 20051201 |
| Effect of FTY720 on chronic cyclosporine nephropathy in rats. | Transplantation 20051115 |
| Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. | The Journal of biological chemistry 20051104 |
| The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20051101 |
| FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. | Journal of clinical pharmacology 20051101 |
| FTY720 inhibits TH1-mediated allogeneic humoral immune response. | Transplantation proceedings 20051101 |
| The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. | The Journal of biological chemistry 20051007 |
| [Multiple sclerosis. A new oral immunomodulator]. | Medizinische Monatsschrift fur Pharmazeuten 20051001 |
| Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates. | Toxicology 20050915 |
| Immunology. Dietary factors and immunological consequences. | Science (New York, N.Y.) 20050909 |
| Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. | Journal of immunology (Baltimore, Md. : 1950) 20050901 |
| Sphingosine-1-phosphate mediates migration of mature dendritic cells. | Journal of immunology (Baltimore, Md. : 1950) 20050901 |
| Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. | Molecular cancer therapeutics 20050901 |
| The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. | Blood 20050815 |
| FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. | Cancer research 20050815 |
| Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. | Journal of medicinal chemistry 20050811 |
| Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement. | Journal of leukocyte biology 20050801 |
| Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. | Bioorganic & medicinal chemistry letters 20050801 |
| [Effects of sphingosine 1-phosphate on functions of T cell - review]. | Zhongguo shi yan xue ye xue za zhi 20050801 |
| Protection of mouse small bowel allografts by FTY720 and costimulation blockade. | Transplantation 20050627 |
| FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. | Transplantation 20050615 |
| Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis. | Journal of magnetic resonance imaging : JMRI 20050601 |
| Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. | Transplantation 20050515 |
| Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20050501 |
| Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. | Circulation research 20050429 |
| A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. | Regulatory peptides 20050415 |
| FTY720 pharmacokinetics in mild to moderate hepatic impairment. | Journal of clinical pharmacology 20050401 |
| FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration. | Pancreas 20050401 |
| A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice. | Biological & pharmaceutical bulletin 20050401 |
| Sphingosine 1-phosphate analogs as receptor antagonists. | The Journal of biological chemistry 20050318 |
| [Study of the effects of immunosuppressive agents on human islet cells in vitro]. | Zhonghua yi xue za zhi 20050316 |
| Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. | Carcinogenesis 20050301 |
| The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050301 |
| On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. | Basic & clinical pharmacology & toxicology 20050301 |
| Fingolimod. Mitsubishi Pharma/Novartis. | IDrugs : the investigational drugs journal 20050301 |
| Preoperative administration of FTY720 prolonged renal allograft survival. | Transplant immunology 20050301 |
| Novel mediators of FTY720 in human lymphocytes. | Transplantation 20050227 |
| FTY720 in corneal concordant xenotransplantation. | Transplantation 20050215 |
| The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. | European journal of immunology 20050201 |
| Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice. | World journal of gastroenterology 20050128 |
| KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. | Circulation 20050118 |
| Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. | Bioorganic & medicinal chemistry 20050117 |
| A convenient synthesis of immunosuppressive agent FTY720 using the petasis reaction. | Chemical & pharmaceutical bulletin 20050101 |
| FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050101 |
| Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. | Annual review of immunology 20050101 |
| [New immunodepressant drugs for the prevention and control of kidney transplant rejection]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20050101 |
| Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate. | Transplantation proceedings 20050101 |
| Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. | Transplantation proceedings 20050101 |
| FTY720 inhibits tumor growth and angiogenesis. | Transplantation proceedings 20050101 |
| Prolonged administration of FTY720 does not cause renal toxicity in mice. | Transplantation proceedings 20050101 |
| Control of intestinal allograft rejection by FTY720 and costimulation blockade. | Transplantation proceedings 20050101 |
| FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. | Transplantation proceedings 20050101 |
| The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs. | Surgery today 20050101 |
| FTY720: mechanism of action and potential benefit in organ transplantation. | Yonsei medical journal 20041231 |
| A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists. | Journal of medicinal chemistry 20041230 |
| FTY720 suppresses humoral immunity by inhibiting germinal center reaction. | Blood 20041215 |
| Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. | The Journal of biological chemistry 20041210 |
| FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. | Carcinogenesis 20041201 |
| Overview of FTY720 clinical pharmacokinetics and pharmacology. | Therapeutic drug monitoring 20041201 |
| Novel immunosuppressants. | Pediatric transplantation 20041201 |
| Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation. | Transplant immunology 20041101 |
| Editorial overview: Tie me up, tie me down: immunosuppressive therapies for the 21st century. | Current opinion in investigational drugs (London, England : 2000) 20041101 |
| A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments. | Transplant international : official journal of the European Society for Organ Transplantation 20041101 |
| Sphingosine mediates FTY720-induced apoptosis in LLC-PK1 cells. | Experimental & molecular medicine 20041031 |
| Modulation of adaptive immune responses by sphingosine-1-phosphate. | Seminars in cell & developmental biology 20041001 |
| Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. | Kidney international 20041001 |
| Effects of FTY720 on rat lymphoid organs. | Transplantation proceedings 20041001 |
| [Immunossupresive drugs in renal transplantation]. | Polskie Archiwum Medycyny Wewnetrznej 20041001 |
| Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720. | Bioorganic & medicinal chemistry 20040915 |
| Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20040901 |
| Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. | Kidney international 20040901 |
| A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. | Biological & pharmaceutical bulletin 20040901 |
| Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine. | The Journal of biological chemistry 20040827 |
| The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801 |
| Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. | Journal of neuroimmunology 20040801 |
| FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. | Journal of immunology (Baltimore, Md. : 1950) 20040715 |
| Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. | Nature immunology 20040701 |
| FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20040701 |
| FTY720--the first compound of a new promising class of immunosuppressive drugs. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040701 |
| FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. | The British journal of ophthalmology 20040701 |
| Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. | Journal of magnetic resonance imaging : JMRI 20040701 |
| Should we B-leavin' now? | Nature immunology 20040701 |
| FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. | Transplantation 20040627 |
| Effect of FTY720 on rat small bowel transplantation. | Transplantation 20040627 |
| Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. | Bioorganic & medicinal chemistry letters 20040621 |
| The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. | Blood 20040615 |
| Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. | American journal of respiratory and critical care medicine 20040601 |
| FTY720 prevents anti-CD4 mAb-induced tolerance but cannot reverse established tolerance in a rat kidney transplantation model. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20040601 |
| Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. | Biochimica et biophysica acta 20040601 |
| ['Vegetable wasps and plant worms' and G-protein-coupled receptors]. | Journal of UOEH 20040601 |
| Future immunosuppressive agents in solid-organ transplantation. | Progress in transplantation (Aliso Viejo, Calif.) 20040601 |
| Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720. | The Journal of organic chemistry 20040528 |
| FTY: not just a homely drug. | Transplantation 20040515 |
| FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. | Transplantation 20040515 |
| Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. | The Journal of pharmacology and experimental therapeutics 20040501 |
| Immunoregulatory lysophospholipids: new stars in the mast cell constellation. | Current allergy and asthma reports 20040501 |
| Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. | British journal of clinical pharmacology 20040501 |
| Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. | Journal of clinical pharmacology 20040501 |
| FTY720 impairs necrosis development after ischemia-reperfusion injury. | Transplantation proceedings 20040501 |
| FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination. | Transplantation proceedings 20040501 |
| Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. | Inflammatory bowel diseases 20040501 |
| Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. | The Journal of biological chemistry 20040402 |
| Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. | Transplantation 20040327 |
| The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040301 |
| FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040301 |
| FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. | Kidney international 20040301 |
| FTY720: from bench to bedside. | Transplantation proceedings 20040301 |
| FTY720: early clinical experience. | Transplantation proceedings 20040301 |
| FTY720 immunomodulation: optimism for improved transplant regimens. | Transplantation proceedings 20040301 |
| The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat. | Pediatric diabetes 20040301 |
| Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. | Nature 20040122 |
| CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20040101 |
| Pharmacologic immunosuppression. | Frontiers in bioscience : a journal and virtual library 20040101 |
| FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. | The Annals of pharmacotherapy 20040101 |
| Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. | Prostaglandins & other lipid mediators 20040101 |
| Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20040101 |
| Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. | Journal of immunology (Baltimore, Md. : 1950) 20031201 |
| Current immunosuppressive agents: efficacy, side effects, and utilization. | Pediatric clinics of North America 20031201 |
| Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. | The Journal of biological chemistry 20031128 |
| Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice. | Transplantation 20031127 |
| Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. | The Journal of biological chemistry 20031121 |
| The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. | FEBS letters 20031106 |
| FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model. | Transplantation 20031027 |
| Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. | Transplantation 20031015 |
| Egress: a receptor-regulated step in lymphocyte trafficking. | Immunological reviews 20031001 |
| Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. | International journal of clinical pharmacology and therapeutics 20031001 |
| [Study the mechanisms and inducing transplantation immune tolerance of FTY720]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20031001 |
| FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation. | Acta pharmacologica Sinica 20030901 |
| Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm. | Current opinion in chemical biology 20030801 |
| Ubiquitin pathway proteins influence the mechanism of action of the novel immunosuppressive drug FTY720 in Saccharomyces cerevisiae. | The Journal of biological chemistry 20030718 |
| Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20030701 |
| FTY720: A new kid on the block for transplant immunosuppression. | Expert opinion on biological therapy 20030701 |
| Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. | The Journal of urology 20030601 |
| The effect of FTY 720 on engraftment in a model of spontaneous allograft acceptance. | Transplant international : official journal of the European Society for Organ Transplantation 20030601 |
| Prevention of renal ischemic reperfusion injury using FTY 720 and ICAM-1 antisense oligonucleotides. | Transplantation proceedings 20030601 |
| FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells. | Transplantation 20030515 |
| Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats. | Transplantation 20030427 |
| FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A. | Transplantation 20030415 |
| Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. | Journal of immunology (Baltimore, Md. : 1950) 20030401 |
| Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. | The Journal of pharmacology and experimental therapeutics 20030401 |
| A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. | British journal of pharmacology 20030401 |
| The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. | Clinical immunology (Orlando, Fla.) 20030401 |
| FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. | The Journal of clinical investigation 20030301 |
| Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. | The Journal of clinical investigation 20030301 |
| Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720. | Bioscience, biotechnology, and biochemistry 20030301 |
| [Effects of three different immunosuppressive drugs on SD rat islet cell viability]. | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20030201 |
| CTLA4Ig-gene transfection with FTY720 administration markedly inhibits the obliterative airway disease in heterotopically transplanted rat tracheas. | Transplantation proceedings 20030201 |
| Pretreatment with FTY720 alone induced long-term survival of mouse heart allograft. | Transplantation proceedings 20030201 |
| Linking Chinese medicine and G-protein-coupled receptors. | Trends in pharmacological sciences 20030101 |
| Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. | Anticancer research 20030101 |
| Renal transplantation: basic concepts and evolution of therapy. | Journal of clinical apheresis 20030101 |
| New paradigms in immunosuppression. | CANNT journal = Journal ACITN 20030101 |
| Different mechanisms for membrane and nuclear damages in apoptosis induced by an immunosuppressant, FTY720. | Molecules and cells 20021231 |
| Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. | Transplantation 20021227 |
| T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. | British journal of pharmacology 20021201 |
| Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. | Transplantation 20021127 |
| Sirolimus and FTY720: new approaches to transplant immunosuppression. | Transplantation proceedings 20021101 |
| Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model. | Transplantation proceedings 20021101 |
| Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. | Transplantation 20021015 |
| Transplantation. | Current opinion in immunology 20021001 |
| FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. | Current opinion in immunology 20021001 |
| FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20021001 |
| Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. | Transplantation 20020915 |
| FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. | Transplantation proceedings 20020901 |
| Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts. | Transplantation proceedings 20020801 |
| FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury. | Transplantation proceedings 20020801 |
| A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. | Cancer letters 20020726 |
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors. | The Journal of biological chemistry 20020614 |
| Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20020601 |
| Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. | Transplantation 20020515 |
| Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. | The Journal of pharmacology and experimental therapeutics 20020501 |
| Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy. | Transplantation proceedings 20020501 |
| Donor pretreatment with FTY720 increases graft lymphocytes but does not affect graft survival following rat small bowel transplantation. | Transplantation proceedings 20020501 |
| Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. | Science (New York, N.Y.) 20020412 |
| First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. | Journal of the American Society of Nephrology : JASN 20020401 |
| Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. | The Journal of rheumatology 20020401 |
| Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. | International journal of cancer 20020310 |
| Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). | The Journal of pharmacology and experimental therapeutics 20020301 |
| Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. | Cancer research 20020301 |
| L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. | Journal of immunology (Baltimore, Md. : 1950) 20020215 |
| Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. | Therapeutic drug monitoring 20020201 |
| What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? | Transplantation 20020127 |
| Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. | International immunopharmacology 20011001 |
| FTY720: altered lymphocyte traffic results in allograft protection. | Transplantation 20010915 |
| [mTOR and FTY 720 inhibitors]. | Presse medicale (Paris, France : 1983) 20010901 |
| [What is new on transplantation in 2001?]. | Presse medicale (Paris, France : 1983) 20010901 |
| Proteasome inhibitors and immunosuppressive drugs promote the cleavage of eIF4GI and eIF4GII by caspase-8-independent mechanisms in Jurkat T cell lines. | FEBS letters 20010817 |
| Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs. | Journal of immunological methods 20010801 |
| Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. | Transplantation 20010715 |
| A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor. | The Journal of pharmacology and experimental therapeutics 20010601 |
| Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. | Japanese journal of cancer research : Gann 20010601 |
| Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. | Journal of the American College of Cardiology 20010501 |
| Neointima suppression in rat carotid allografts by FTY720 combined with a small fixed cyclosporine dose is related to a diminution of the peripheral lymphocyte count. | Transplantation proceedings 20010501 |
| FTY-720 is efficacious in monkey kidney transplantation. | Transplantation proceedings 20010501 |
| Long-term graft acceptance in rat heart transplantation by CTLA4Ig gene transfection combined with FTY720 treatment. | World journal of surgery 20010401 |
| New immunosuppressive drugs: an update. | Current opinion in urology 20010301 |
| Treatment of transplant rejection: are the traditional immunosuppressants good enough? | Current opinion in investigational drugs (London, England : 2000) 20010301 |
| FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. | Biochemical and biophysical research communications 20010223 |
| Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720. | Clinical and experimental immunology 20010201 |
| Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models. | Transplant immunology 20010201 |
| Immunosuppressive drugs in paediatric liver transplantation. | Paediatric drugs 20010101 |
| FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. | Transplantation proceedings 20010101 |
| FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. | Transplantation proceedings 20010101 |
| FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. | Transplantation proceedings 20010101 |
| FTY 720 prevents ischemic reperfusion damage in rat kidneys. | Transplantation proceedings 20010101 |
| FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. | Transplantation proceedings 20010101 |
| FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. | Transplantation proceedings 20010101 |
| FTY720: a new dimension in transplantation. | Transplantation proceedings 20010101 |
| T-cell apoptosis triggered by FTY720 via mitochondrial pathway. | Transplantation proceedings 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.